Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also benefit from EGFR inhibitors (Merck & Co. / Eli Lilly’s Erbitux and Amgen’s Vectibix), which are recommended for first-line treatment of patients with left-sided tumors. Notably, additional targeted therapies for specific molecular subtypes have been developed: immune checkpoint inhibitors (Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo and Yervoy) for MSI-high and/or MMR-deficient tumors; BRAF inhibitors (Array BioPharma / Pfizer’s Braftovi) for metastatic colorectal cancer with a BRAF V600E mutation; and HER2-targeted agents in some markets (Chugai’s Perjeta and trastuzumab and Seagen’s Tukysa) for HER2-positive metastatic disease. Most therapies in late-stage development are intended to treat other genomic alterations (i.e., KRAS G12C mutation) or expand the immunotherapy-based approaches for treating MSS and/or pMMR tumors.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENTS
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast also features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.